Naltrexone And Bupropion
Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)
Orexigen Therapeutics, Inc · Phase 2/3 · Completed · Enrollment 92
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication | n/r | n/r | n/r | n/r |
| BWL + Placebo | n/r | n/r | n/r | n/r |
| NB medication | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication: endpoint not reported
- BWL + Placebo: endpoint not reported
- NB medication: endpoint not reported
- Placebo: endpoint not reported